Fortrea Holdings Inc.(FTRE)
$19.59-0.20 (-1.01%)
FTRE
Fortrea Holdings Inc. stock drug pipeline
$19.59
At close:-0.20 (-1.01%)
Want to see FTRE full AI Analyst Report?
Fortrea Holdings Inc. (FTRE) Drug Pipeline
118 Followers
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Fortrea Holdings Inc. (FTRE) have in its pipeline
Fortrea Holdings Inc. FTRE is currently developing the following drugs: Geh300079 (68Ga) Injection Positron-Emission Tomography (Pet)/Computed Tomography (Ct), D3s-001, Ap301, Ap301 Low Dose, Givinostat Hydrochloride, Givinostat Hydrochloride - Cohort 2, Ath-1105, Geh200520 Injection And Geh200521 (18F) Injection, Static - Pet/Ct Scan, Givinostat, Altropane (123I) Injection, Leniolisib, Vit-2763 120 Mg, Vit-2763 360 Mg, Vit-2763 240 Mg, Rivaroxaban, Abelacimab. These drug candidates are in various stages of clinical development as the company works toward FDA approval.

